Short answer
COLLEGIUM PHARMACEUTICAL, INC (COLL) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $194M (up 8.9% year over year) with net income of $14M.
Q1 2026 key financials · XBRL
- Revenue
- $194M
- +8.9% YoY
- Net income
- $14M
- +499.8% YoY
- Operating margin
- 16.0%
- Gross margin
- 60.6%
- EPS (diluted)
- $0.40
- +471.4% YoY
Source: XBRL data from the COLLEGIUM PHARMACEUTICAL, INC (COLL) Q1 2026 10-Q on SEC EDGAR. USD.
COLLEGIUM PHARMACEUTICAL, INC Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Product revenue $193.5M, up $15.7M YoY from $177.8M, led by Jornay PM growth of $10.4M
- Gross margin 60.6% vs 54.7% YoY; operating margin 16.0% vs 12.2%
- Best performer Jornay PM revenue increase $10.4M; worst Nucynta Products revenue decrease $0.1M
- Cash, equivalents and marketable securities $421.8M; operating cash flow $57.1M vs $55.4M
- Azstarys acquisition expected Q2 2026 for $650M upfront cash; generic Nucynta launches create competitive headwinds
Risk Factors
- Newly triggered acquisition risk from AZSTARYS purchase: integration delays could prevent anticipated benefits
- Debt burden: $572.8 million 2025 Term Loan plus $241.5 million 2029 Convertible Notes
- FDA opioid labeling changes announced July 31, 2025 require expanded warnings and dosing guidance
- Promotional compliance risk heightened by FDA’s September 2025 scrutiny of direct-to-consumer advertising
- Floating-rate exposure: 2025 Credit Agreement priced at term SOFR plus 2.75%–3.75% without hedging
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other COLLEGIUM PHARMACEUTICAL, INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.